Clinical Trial Update: Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001) [Phase 2]

View source ↗

Summary

Phase 2 trial to determine the maximum tolerated dose of Org 26576 in participants with major depressive disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Org 26576

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Depression | Phase 2 | Status: COMPLETED | Results posted: 2014-07-02